Coffee and Liver Health: Evidence-Based Benefits for MASLD, Cirrhosis, and Liver Cancer
1. Coffee and Liver Disease: The Evidence
Coffee is one of the most widely consumed beverages globally, with over 2 billion cups consumed daily worldwide. In recent years, accumulating evidence has emerged suggesting that regular coffee consumption may exert protective effects on liver health and influence the progression of several liver diseases. Specifically, epidemiological and mechanistic studies have investigated the relationship between coffee intake and metabolic-associated steatotic liver disease (MASLD; formerly known as non-alcoholic fatty liver disease [NAFLD]), hepatic fibrosis and cirrhosis, and the risk of hepatocellular carcinoma (HCC).
This chapter presents an evidence-based overview of the potential benefits of coffee in these contexts, examines different types of coffee beans and preparation methods (instant versus brewed; Arabica versus Robusta; filtered versus unfiltered), and outlines mechanistic and clinical considerations. Understanding the relationship between coffee consumption and liver health has important implications for preventive medicine and patient counseling, particularly given coffee’s widespread availability, low cost, and general safety profile.
Think of your liver as your body’s main processing plant—it filters toxins, produces important proteins, and helps digest food. Sometimes this plant can get damaged through various factors like obesity, alcohol, or viral infections.
What researchers have discovered is that coffee, one of the world’s most popular drinks, might actually help protect this vital organ. Multiple large studies involving hundreds of thousands of people have shown that those who drink coffee regularly tend to have healthier livers and lower rates of serious liver problems like scarring (cirrhosis) and liver cancer. It’s as if coffee provides a shield that helps your liver do its job better and resist damage.
1.1 Coffee and Cirrhosis / Fibrosis
Hepatic fibrosis is the buildup of scar tissue in the liver, typically as a wound-healing response to chronic injury. When fibrosis becomes advanced and distorts the liver architecture, it progresses to cirrhosis, which is characterized by regenerative nodules surrounded by fibrous tissue. Cirrhosis represents an irreversible end-stage of various chronic liver diseases and is associated with significant morbidity and mortality.
Multiple meta-analyses have systematically examined the association between coffee intake and the risk of cirrhosis and hepatic fibrosis. A landmark meta-analysis by Kennedy et al. (2016), incorporating nine studies (five cohort studies and four case-control studies) with approximately 432,133 participants and 1,990 cirrhosis cases, found that an increase of two cups of coffee per day was associated with a pooled relative risk of cirrhosis of approximately 0.56 (95% confidence interval [CI] 0.44-0.68). This translates to a remarkable 44% reduction in cirrhosis risk for those consuming an additional two cups daily.
An earlier study by Klatsky et al. (2006) and another meta analysis (Liu et al 2015) demonstrated a pooled odds ratio for developing cirrhosis of 0.61 (95% CI 0.45-0.84) when comparing coffee drinkers to non-drinkers. The consistency of these findings across different study designs and populations strengthens the evidence for a protective association.
Furthermore, in patients with NAFLD (now termed MASLD), a meta-analysis by Ebadi et al. (2021) found that coffee consumption was associated with a 35% decreased odds of significant liver fibrosis (relative risk [RR] 0.65, 95% CI 0.54–0.78). This suggests that coffee may not only prevent the development of cirrhosis in the general population but may also slow the progression of existing fibrotic disease in at-risk individuals.
These epidemiological data collectively suggest that coffee consumption may attenuate the progression of hepatic fibrosis and potentially delay or prevent the onset of cirrhosis. The dose-response relationship observed in several studies indicates that the protective effect may be enhanced with higher consumption levels, typically in the range of two to four cups per day.
1.2 Coffee and Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma is the most common primary malignancy of the liver and represents top 10 leading cause of cancer-related mortality worldwide. HCC typically develops in the setting of chronic liver disease and cirrhosis, with major risk factors including chronic hepatitis B or C infection, alcohol-related liver disease, MASLD, and aflatoxin exposure.
The evidence linking coffee consumption to reduced HCC risk is particularly robust and consistent. A comprehensive meta-analysis by Bravi et al. (2013), which included 16 studies encompassing 3,153 HCC cases, reported a pooled relative risk of 0.60 (95% CI 0.50-0.71) for any coffee consumption versus none. This represents a 40% reduction in HCC risk associated with regular coffee consumption. Notably, higher consumption levels were associated with even stronger risk reduction, with a relative risk of approximately 0.44 for high consumption categories, suggesting a dose-response relationship.
Another systematic review and meta-analysis by Larsson and Wolk (2007) found summary relative risks for HCC of approximately 0.66 (95% CI 0.55–0.78) for regular coffee consumption versus none, and for chronic liver disease mortality of approximately 0.50 (95% CI 0.43–0.58). The magnitude and consistency of these associations across diverse populations and study designs provide compelling evidence for a protective effect.
The mechanisms by which coffee may reduce HCC risk likely involve multiple pathways, including reduction of inflammation and fibrosis (which provide the milieu for carcinogenesis), as well as potential direct anti-carcinogenic effects of coffee constituents.
1.3 Coffee and MASLD (Non-Alcoholic Fatty Liver Disease) / Liver Steatosis
Metabolic-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is characterized by excessive fat accumulation in the liver (hepatic steatosis) in the absence of significant alcohol consumption. MASLD has become the most common chronic liver disease worldwide, with an estimated global prevalence of 25-30%. The condition exists on a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), which involves inflammation and hepatocyte injury, and can progress to fibrosis, cirrhosis, and HCC.
Emerging evidence suggests that coffee consumption may reduce the risk of MASLD development and slow disease progression. A meta-analysis by Wijarnpreecha et al. (2017) found that among coffee drinkers, the risk of NAFLD was significantly lower, with a pooled relative risk of 0.71 (95% CI 0.60-0.85), representing a 29% risk reduction. Furthermore, among individuals already diagnosed with NAFLD, coffee consumption was associated with reduced risk of liver fibrosis (pooled RR 0.70, 95% CI 0.60-0.82).
These findings were corroborated by Ebadi et al. (2021), who concluded that coffee consumption was significantly associated with a 35% decreased odds of significant fibrosis (RR 0.65, 95% CI 0.54–0.78) in NAFLD patients. A comprehensive review by Kositamongkol et al. (2021) summarized numerous studies demonstrating favorable associations between coffee consumption and reductions in fatty liver disease, steatosis severity, and fibrosis progression.
These findings are complemented by studies examining intermediate biomarkers of liver health. For example, Niezen et al. (2022) found that coffee consumption was associated with lower liver stiffness measurements in patients with non-alcoholic liver disease.
The potential mechanisms by which coffee may benefit MASLD include improvement in insulin sensitivity, reduction in hepatic fat accumulation, attenuation of oxidative stress and inflammation, and modulation of lipid metabolism. These effects are particularly relevant given the close relationship between MASLD and metabolic syndrome, insulin resistance, and type 2 diabetes.
1.4 Summary of Clinical Evidence
The cumulative epidemiological evidence regarding coffee and liver health can be synthesized as follows:
Cirrhosis and Fibrosis: Regular coffee consumption, typically in the range of two to three cups per day or more, is associated with approximately 40-60% lower risk of cirrhosis in large observational studies. The protective association extends to patients with existing chronic liver disease, in whom coffee may slow fibrosis progression.
Hepatocellular Carcinoma: Coffee consumption is associated with approximately 40% lower risk of HCC in multiple meta-analyses, with evidence of a dose-response relationship. This protective association is observed across different populations and etiologies of liver disease.
MASLD and Steatosis: Among individuals with fatty liver disease, coffee intake is linked to lower prevalence of hepatic steatosis and fibrosis, as well as slower disease progression. The strength of evidence is substantial, though slightly less robust than for cirrhosis and HCC outcomes.
Important Caveats: It is crucial to emphasize that these are observational data derived from cohort and case-control studies. While the consistency and magnitude of associations are impressive, causality cannot be definitively established. Residual confounding may exist, for example, coffee drinkers may differ from non-drinkers in other health behaviors. Additionally, optimal dose, timing of consumption, specific coffee type, and preparation method remain to be definitively established through randomized controlled trials.
2. How Might Coffee Confer Hepatoprotection? Mechanistic Insights
2.1 Bioactive Compounds in Coffee
Coffee is a remarkably complex beverage containing hundreds of bioactive compounds beyond caffeine. The major classes of bioactive constituents include:
Chlorogenic Acids (CGAs): These are a family of phenolic compounds that represent one of the most abundant groups of antioxidants in coffee. CGAs include caffeoylquinic acids, feruloylquinic acids, and dicaffeoylquinic acids. They exhibit potent antioxidant properties and may modulate glucose metabolism and lipid profiles.
Caffeine: The most well-known coffee constituent, caffeine (1,3,7-trimethylxanthine) is a methylxanthine alkaloid that acts as a central nervous system stimulant and has been shown to have diverse metabolic effects.
Diterpenes: Kahweol and cafestol are diterpene compounds present in coffee oil. Their concentrations vary significantly depending on brewing method, with paper-filtered coffee containing minimal amounts. These compounds have demonstrated anti-carcinogenic properties in experimental models but may also raise serum cholesterol levels.
Trigonelline: This alkaloid is present in relatively high concentrations in coffee and may have neuroprotective and metabolic benefits.
Melanoidins: These are brown, high-molecular-weight compounds formed during the roasting process through Maillard reactions. They contribute to coffee’s antioxidant capacity and may have prebiotic effects.
Polyphenols and Other Antioxidants: Coffee contains various other phenolic compounds, quinides, and lactones that contribute to its overall antioxidant capacity.
A critical observation from the literature is that both regular and decaffeinated coffee demonstrate preventive effects on chronic liver diseases, including fibrosis, cirrhosis, and HCC, as documented in a review by Di Pietrantonio et al. (2024) focusing on caffeine and chlorogenic acids. This indicates that non-caffeine components, particularly chlorogenic acids and polyphenols, contribute significantly to the hepatoprotective effects.
2.2 Antioxidant, Anti-Inflammatory, Anti-Fibrotic Effects
The hepatoprotective mechanisms of coffee are multifaceted and operate at various molecular and cellular levels:
Reduction of Oxidative Stress: Chronic liver diseases are characterized by increased oxidative stress, with accumulation of reactive oxygen species (ROS) that damage cellular components including lipids, proteins, and DNA. Coffee’s rich antioxidant content, particularly chlorogenic acids and polyphenols, can neutralize free radicals and reduce oxidative damage in hepatic tissue, as reviewed by Kositamongkol et al. (2021).
Anti-Inflammatory Effects: Chronic inflammation is a hallmark of progressive liver disease. Coffee constituents have been shown to modulate inflammatory signaling pathways, reducing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). This anti-inflammatory activity may help attenuate the inflammatory cascade that drives disease progression.
Inhibition of Hepatic Stellate Cell Activation: Hepatic stellate cells are the primary drivers of liver fibrosis. When activated in response to liver injury, these cells transform into myofibroblasts and produce excessive extracellular matrix proteins, leading to fibrosis. Coffee compounds, particularly chlorogenic acids, have been shown to suppress hepatic stellate cell activation through inhibition of transforming growth factor-beta (TGF-β) signaling pathways, as described by Kositamongkol et al. (2021).
Improvement in Insulin Sensitivity and Lipid Metabolism: MASLD is intimately linked with insulin resistance and metabolic dysfunction. Coffee consumption has been associated with improved insulin sensitivity and favorable modulation of lipid metabolism, which may reduce hepatic fat accumulation and subsequent lipotoxicity. A study by Shokouh et al. (2019) in a rodent model of type 2 diabetes demonstrated that both Arabica and Robusta coffee improved insulin resistance and reduced liver steatosis.
Modulation of Liver Enzyme Levels: Coffee consumption has been inversely associated with serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), which are biomarkers of hepatocellular injury. Xiao et al. (2014) found in NHANES data that both caffeinated and decaffeinated coffee were inversely associated with elevated liver enzymes, supporting the role of non-caffeine components.
Anti-Carcinogenic Effects: Coffee may reduce HCC risk through multiple mechanisms. First, by reducing inflammation and fibrosis, coffee diminishes the substrate upon which HCC typically develops. Second, coffee constituents may have direct anti-cancer effects, including induction of apoptosis in cancer cells, inhibition of cell proliferation, and modulation of cancer-related signaling pathways, as reviewed by Godos et al. (2014).
To understand how coffee might protect the liver, imagine your liver cells are workers in a factory that’s under constant attack from harmful substances. Coffee contains hundreds of natural protective compounds—think of them as a security team. Some of these guards (like chlorogenic acids) are antioxidants that neutralize dangerous molecules before they can damage your liver cells. Others help calm down inflammation, which is like putting out small fires before they spread. Coffee also seems to prevent the buildup of scar tissue in the liver, which is important because too much scarring can lead to cirrhosis. Additionally, coffee helps your body use insulin better and process fats more efficiently, which is especially helpful if you have a fatty liver. Interestingly, even decaffeinated coffee provides many of these benefits, showing that it’s not just the caffeine doing the work, it’s the whole team of natural compounds in the coffee bean.
2.3 Dose-Response and Safety Considerations
Several meta-analyses have documented a dose-response relationship between coffee consumption and liver outcomes. For example, the analysis by Larsson and Wolk (2007) reported that each additional cup of coffee per day was associated with further reduction in risk of HCC and chronic liver disease mortality. Similarly, the meta-analysis on cirrhosis found that incrementally increasing coffee consumption by two cups per day corresponded to progressively lower cirrhosis risk.
Based on the available evidence, the threshold for benefit appears to be approximately two to three cups per day, with potential for additional benefit up to four or more cups daily. However, it is important to note that very high consumption levels (more than five to six cups daily) have not been extensively studied in the context of liver disease and may be associated with other health considerations.
Safety Profile: In the context of liver disease, the available evidence suggests that coffee consumption is generally safe and may be beneficial. The British Liver Trust (2023) states that “Lots of studies have looked at coffee and liver health. Overall these found that drinking coffee is likely to be good for your liver.” their detailed FAQs do emphasize that coffee is not a substitute for appropriate medical care.
It is also important to consider that the addition of sugar, cream, artificial sweeteners, and flavored syrups may offset the metabolic benefits of coffee, particularly in patients with MASLD or metabolic syndrome. Clinicians should counsel patients to consume coffee with minimal additives.
3. Types of Coffee Beans, Varieties & Relevance for Liver Health
3.1 Arabica vs Robusta
The two main commercially cultivated coffee species are Coffea arabica (Arabica) and Coffea canephora (Robusta). These species differ in their cultivation requirements, taste profiles, and chemical composition, which may have implications for health outcomes.
Coffea arabica (Arabica): Arabica coffee accounts for approximately 60-80% of global coffee production. It is typically grown at higher altitudes (600-2000 meters), has a milder, more nuanced flavor profile, and contains lower caffeine content (approximately 1.2-1.5% by weight) compared to Robusta. Arabica beans generally contain higher levels of trigonelline and lipids.
Coffea canephora (Robusta): Robusta coffee comprises approximately 20-40% of global production. It is more disease-resistant, can be grown at lower altitudes, has a stronger, more bitter taste, and contains higher caffeine content (approximately 2.2-2.7% by weight). Importantly, Robusta beans have been documented to exhibit higher chlorogenic acid (CGA) content compared to Arabica, as noted in an Indian agricultural review, which may contribute to stronger antioxidant potential.
Evidence in Liver Disease Context: A rodent study by Shokouh et al. (2019) compared the effects of long-term consumption of Arabica versus Robusta coffee in a rat model of type 2 diabetes. The study found that both species reduced weight gain, improved insulin resistance, and decreased liver steatosis, with no significant difference between the two varieties. This suggests that both Arabica and Robusta coffees possess hepatoprotective properties.
From a theoretical standpoint, Robusta’s higher chlorogenic acid and caffeine content might suggest greater hepatoprotective potential. Conversely, Arabica’s higher trigonelline content may offer unique benefits, as trigonelline has demonstrated protective effects in various metabolic conditions. However, it is crucial to note that human clinical trials specifically comparing liver disease outcomes between Arabica and Robusta consumers are lacking. The observational epidemiological studies demonstrating coffee’s benefits have typically not distinguished between coffee species, suggesting that both varieties are likely beneficial.
3.2 Bean Quality, Roasting, Processing
Beyond species selection, several factors influence the bioactive compound profile of coffee:
Bean Quality and Cultivation: Growing conditions including altitude, soil composition, climate, and agricultural practices affect the concentrations of bioactive compounds in coffee beans. Higher-altitude coffees (typically Arabica) often have higher chlorogenic acid content due to slower bean maturation.
Processing Method: Coffee can be processed using the wet (washed) method, dry (natural) method, or semi-washed methods. These processing techniques affect the final chemical composition and flavor profile of the beans.
Roasting Level: Roasting is a critical determinant of coffee’s chemical profile. Light roasts generally retain higher levels of chlorogenic acids, as these compounds are partially degraded during prolonged roasting. However, roasting also produces melanoidins and other Maillard reaction products that have their own antioxidant and beneficial properties. Dark roasts contain lower chlorogenic acid levels but may have enhanced anti-inflammatory properties through other mechanisms. The relationship between roasting level and health outcomes is complex and incompletely understood.
Storage and Freshness: Oxidation and degradation of beneficial compounds occurs over time, particularly after grinding. Freshly ground coffee from recently roasted beans likely retains higher levels of bioactive constituents compared to pre-ground coffee that has been stored for extended periods.
Because liver-protective benefits may derive from the collective effects of polyphenols, diterpenes, trigonelline, and other compounds, variations in roasting and processing likely influence effect magnitude, although comprehensive human clinical data comparing these variables are scarce.
3.3 Practical Considerations for Bean Choice
For patients with liver disease or those at risk (such as individuals with MASLD, chronic hepatitis, or alcohol-related liver disease), while definitive guidelines by bean variety are not established, several reasonable recommendations can be made:
Quality Selection: Choose higher-quality beans (such as 100% Arabica or specialty Robusta blends) if budget permits. Higher-quality coffees typically have fewer defects and adulterants, and may have more controlled cultivation and processing.
Moderate Consumption: Based on observational evidence, aim for moderate consumption in the range of two to four cups per day. This appears to be the sweet spot for hepatoprotective benefits without excessive caffeine intake.
Minimal Additives: Avoid adding large amounts of sugar, cream, whipped toppings, or flavored syrups, which may offset the metabolic benefits of coffee. These additives contribute excess calories, saturated fat, and simple sugars that may worsen metabolic dysfunction.
Variety Consideration: While both Arabica and Robusta appear beneficial, individuals may choose based on taste preference and tolerance. Those sensitive to caffeine may prefer Arabica due to its lower caffeine content, or may opt for decaffeinated varieties.
Organic Options: While not specifically studied in the liver disease context, organic coffee avoids potential exposure to pesticide residues, which may be a consideration for patients with compromised liver function.
4. Coffee Preparation and Type: Instant vs Brewed vs Other
The method of coffee preparation significantly influences the final chemical composition of the beverage and may affect health outcomes. Different brewing methods extract varying amounts and proportions of bioactive compounds, and the presence or absence of filtration affects the levels of specific constituents, particularly diterpenes.
4.1 Brewed Coffee (Ground, Filtered, Espresso)
Brewed coffee encompasses various preparation methods including drip coffee with paper filters, pour-over methods, and espresso. The evidence suggests that brewed coffee, particularly when filtered, is associated with equally protective or greater effects compared to other types.
Epidemiological Evidence: In a large UK Biobank cohort study by Kennedy et al. (2021) involving 494,585 participants, ground coffee (which includes espresso) demonstrated the largest effect size for chronic liver disease outcomes compared to instant or decaffeinated coffee. Ground coffee consumption was associated with approximately 21% reduced risk of chronic liver disease compared to non-consumers, and showed the strongest associations with reduced liver-related mortality.
Filtered Coffee Advantages: Paper filtration removes most diterpenes (kahweol and cafestol), which are present in coffee oils. While these diterpenes may have some anti-carcinogenic properties, they are also known to raise LDL cholesterol and total cholesterol levels, which may be undesirable in patients with cardiovascular risk factors. Therefore, filtered brewed coffee may offer dual benefits: hepatoprotection combined with cardiovascular safety. This is particularly relevant given that many patients with liver disease also have metabolic syndrome and cardiovascular comorbidities.
Espresso Considerations: Espresso is a concentrated form of coffee brewed by forcing hot water through finely ground coffee under high pressure. While espresso contains minimal diterpenes due to the small serving size and brief extraction time, it does provide a concentrated dose of caffeine and chlorogenic acids. Espresso-based beverages can be beneficial if consumed without excessive sugar or fatty additives.
4.2 Instant Coffee
Instant coffee is produced by brewing coffee and then removing the water through freeze-drying or spray-drying processes. This results in soluble coffee granules or powder that can be quickly reconstituted with hot water.
Evidence Base: The UK Biobank study by Kennedy et al. (2021) found that instant coffee consumption was also associated with reduced risk of chronic liver disease and death from chronic liver disease, though the effect size was somewhat smaller than that observed for ground coffee. This demonstrates that despite processing, many beneficial compounds survive the instant coffee manufacturing process.
Practical Advantages: Instant coffee offers convenience, longer shelf life, and lower cost compared to whole bean or ground coffee. This makes it an accessible option in settings where brewing equipment is unavailable or impractical.
Considerations: The quality of instant coffee can vary considerably by brand and manufacturing process. Some instant coffees may contain additives, including maltodextrin, sodium, or other ingredients. Additionally, instant coffee typically has lower caffeine content than brewed coffee (approximately 30-90 mg per cup versus 80-100 mg for brewed coffee). However, chlorogenic acids and other polyphenolic compounds are substantially retained in instant coffee, which likely accounts for the observed protective associations.
4.3 Decaffeinated Coffee
Decaffeinated coffee is produced by extracting caffeine from green (unroasted) coffee beans using various methods including water processing, carbon dioxide processing, or solvent-based methods. The decaffeination process removes approximately 97% or more of the original caffeine content.
Evidence for Benefit: Interestingly, decaffeinated coffee also shows protective associations with liver disease outcomes, albeit sometimes of lesser magnitude than caffeinated coffee. A meta-analysis by Poole et al. (2017) indicated that increased caffeinated coffee consumption had a stronger inverse association with reduced HCC risk, but decaffeinated coffee also demonstrated a protective trend. The study by Xiao et al. (2014) found that both caffeinated and decaffeinated coffee were inversely associated with elevated liver enzymes in a large US population, supporting the importance of non-caffeine constituents.
Clinical Applications: Decaffeinated coffee represents an important option for patients who cannot tolerate caffeine due to medical conditions such as cardiac arrhythmias, anxiety disorders, insomnia, or gastroesophageal reflux disease. It allows these individuals to potentially benefit from coffee’s hepatoprotective effects without caffeine-related adverse effects.
Constituent Profile: While decaffeination removes caffeine, it preserves significant amounts of chlorogenic acids, polyphenols, and other bioactive compounds. Some studies suggest that certain decaffeination methods may slightly reduce the content of some polyphenols, but substantial amounts remain.
4.4 Unfiltered Coffee and Diterpenes
Unfiltered coffee preparation methods include French press (cafetière), Turkish coffee, Scandinavian boiled coffee, and some espresso preparations. These methods do not employ paper filtration and therefore retain coffee oils containing the diterpenes kahweol and cafestol.
Diterpene Effects: Kahweol and cafestol are terpenoid compounds that have demonstrated anti-carcinogenic and anti-inflammatory properties in experimental studies. However, they also stimulate cholesterol synthesis in the liver and inhibit cholesterol degradation, resulting in elevated serum LDL cholesterol levels. Regular consumption of unfiltered coffee has been shown to raise LDL cholesterol by 6-8% and total cholesterol by approximately 10%, as documented in studies reviewed in PMC resources.
Clinical Implications: While diterpenes may contribute to hepatoprotective effects, the net health outcome for a patient with liver disease who may also have metabolic and cardiovascular comorbidities must balance potential liver benefits against cardiovascular risks. For patients with hyperlipidemia, cardiovascular disease, or those at high cardiovascular risk, unfiltered coffee may warrant caution.
Individual Variation: Cholesterol response to diterpenes varies among individuals based on genetic factors, baseline lipid levels, and other dietary factors. Some patients may tolerate unfiltered coffee without significant lipid elevations.
4.5 Summary of Preparation Type Considerations
Based on the available evidence and clinical considerations:
Optimal Choice: Filtered (paper) ground coffee appears to be the preferred preparation method, given its strong hepatoprotective associations and favorable cardiovascular profile through removal of cholesterol-raising diterpenes.
Acceptable Alternative: Instant coffee represents a viable alternative, especially in settings where brewed coffee is less accessible or convenient. It retains substantial hepatoprotective properties at lower cost.
Decaffeinated Option: Decaffeinated coffee may still offer benefit and should be recommended when caffeinated coffee is contraindicated due to specific medical conditions or medication interactions.
Unfiltered Coffee Caution: Unfiltered high-diterpene coffee (French press, Turkish coffee) may warrant caution in patients with hyperlipidemia or cardiovascular risk factors, though liver benefits may still exist. Lipid profiles should be monitored if these methods are preferred.
Avoid Additives: Regardless of preparation method, additives such as sugar, cream, syrups, and whipped toppings should be minimized, as they may blunt metabolic benefits and contribute to weight gain and insulin resistance.
5. Application to MASLD Progression, Cirrhosis and HCC Risk in Clinical Practice
5.1 MASLD (Reversal / Slowing Progression)
Metabolic-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease in developed countries and is closely linked with obesity, type 2 diabetes, and metabolic syndrome. Current management focuses on lifestyle interventions including weight loss, dietary modification, increased physical activity, and management of metabolic comorbidities. There are limited pharmacological options specifically approved for MASLD/MASH.
In this context, coffee consumption may represent a valuable adjunctive strategy. While direct randomized controlled trials of “coffee intervention” for MASLD are lacking, the observational data are compelling. A systematic review by Sewter et al. (2021) concluded that higher coffee consumption was associated with lower severity of hepatic fibrosis in individuals with NAFLD. The meta-analysis by Ebadi et al. (2021) found that coffee was associated with a 35% reduction in significant fibrosis among NAFLD patients.
Clinical Application: For patients with MASLD, particularly those with evidence of metabolic dysfunction-associated steatohepatitis (MASH) or fibrosis, moderate coffee consumption may contribute to slowing disease progression. In addition to evidence-based lifestyle interventions (targeting 7-10% weight loss through caloric restriction and aerobic exercise, Mediterranean or low-carbohydrate diet patterns), clinicians may consider advising eligible patients: “If you tolerate coffee well, consuming approximately two to four cups per day of brewed filtered coffee may provide additional benefit for liver health, as part of a comprehensive approach to managing your fatty liver disease.”
Patient Selection: Not all MASLD patients will be appropriate candidates for this recommendation. Considerations include: - Tolerance to caffeine (some patients may experience insomnia, anxiety, or palpitations) - Cardiovascular comorbidities that may be affected by caffeine - Gastroesophageal reflux disease (which may be exacerbated by coffee) - Medication interactions (caffeine can interact with certain medications) - Patient preferences and cultural factors
For patients who cannot tolerate caffeinated coffee, decaffeinated varieties may still provide benefit.
5.2 Cirrhosis Prevention / Slowed Progression
In patients with chronic liver disease at risk of progression to cirrhosis—including those with MASLD and significant fibrosis, chronic viral hepatitis (hepatitis B or C), alcohol-related liver disease, autoimmune hepatitis, or other etiologies—coffee may play a preventive or disease-modifying role.
Evidence Base: The meta-analysis findings demonstrate substantially lower risk of cirrhosis development with higher coffee intake, with a relative risk of approximately 0.56 for an increase of two cups per day. This suggests that coffee may reduce the rate of fibrogenesis or slow progression from earlier stages of fibrosis to cirrhosis.
Clinical Application: For patients with chronic liver disease and fibrosis (stage F2 or F3 by liver biopsy or non-invasive assessment), coffee consumption may be recommended as an adjunctive measure alongside primary disease-specific therapies. Primary treatments should include: - Antiviral therapy for viral hepatitis - Complete alcohol abstinence for alcohol-related liver disease - Weight loss and metabolic optimization for MASLD - Immunosuppression for autoimmune hepatitis - Management of other specific etiologies
Coffee should be presented as a complementary strategy that may provide additional benefit but should not replace evidence-based primary therapies.
Established Cirrhosis: In patients with established cirrhosis, the effect of coffee on disease reversal has not been proven. However, observational data suggest that coffee consumption may still provide benefit by potentially slowing further decompensation and reducing HCC risk. In decompensated cirrhosis (Child-Pugh class B or C), individualized assessment is necessary, as these patients may have altered drug metabolism, varices (where hot beverages may pose risk), or other complications that affect coffee tolerance.
5.3 HCC Risk Reduction
Given the consistent observational evidence demonstrating approximately 40% reduced HCC risk in coffee drinkers, incorporating coffee consumption recommendations into a comprehensive liver cancer prevention strategy may be prudent.
Risk Stratification: Patients at elevated HCC risk include those with: - Cirrhosis of any etiology - Chronic hepatitis B infection (even without cirrhosis in some populations) - Advanced fibrosis (stage F3) - MASLD with diabetes and advanced fibrosis - Prior history of HCC (recurrence prevention)
Clinical Application: For patients in these high-risk categories who are eligible for HCC surveillance (typically via ultrasound and alpha-fetoprotein every six months), coffee consumption may provide incremental risk reduction. While coffee should never replace standard surveillance practices, it represents a low-cost, accessible intervention that may complement other preventive measures.
Counseling Approach: When discussing HCC prevention with high-risk patients, clinicians might state: “In addition to your regular liver cancer screening, treating the underlying liver disease, and maintaining a healthy lifestyle, research suggests that drinking two to four cups of coffee daily may help reduce your risk of developing liver cancer. This is based on large observational studies, and while we cannot guarantee it will prevent cancer, it appears to be a safe and potentially beneficial addition to your overall care plan.”
If you’ve been told you have a fatty liver, liver scarring (fibrosis), or are at risk for liver cancer, you might wonder what you can do beyond taking medications and losing weight.
Here’s the interesting part: drinking coffee might actually help. Think of it this way, if you drink about 2-4 cups of coffee per day (preferably brewed with a paper filter and without lots of sugar and cream), studies show you might cut your risk of liver problems roughly in half. That’s significant! However, coffee isn’t a magic cure. You still need to do the important things like maintaining a healthy weight, exercising, avoiding alcohol if advised, and taking any medications your doctor prescribes. Think of coffee as a helpful teammate in your overall liver health strategy, not as the sole player. And if caffeine makes you jittery or anxious, you can try decaf coffee, which still seems to have many of the liver-protecting benefits.
5.4 Caveats and Practical Advice
While the evidence supporting coffee’s hepatoprotective effects is substantial, several important caveats and practical considerations must be emphasized:
Coffee is NOT a Substitute for Primary Therapies: Coffee should never replace evidence-based medical treatments. For example: - Weight loss remains the cornerstone of MASLD management - Antiviral therapy is essential for chronic hepatitis B and C - Alcohol abstinence is mandatory for alcohol-related liver disease - Immunosuppression is necessary for autoimmune hepatitis Coffee should be positioned as an adjunctive, supportive measure within a comprehensive treatment plan.
Optimal Dose Considerations: Many studies show benefit at approximately two to four cups per day. However, the optimal “dose” for hepatoprotection remains uncertain. Individual tolerance varies, and there is no clear evidence that consuming more than four cups daily provides additional benefit. Very high consumption (more than six cups daily) has not been well-studied and may be associated with adverse effects such as insomnia, anxiety, increased blood pressure, or bone loss.
Caffeine Tolerance and Contraindications: Some patients cannot tolerate caffeine due to: - Cardiac arrhythmias (atrial fibrillation, premature ventricular contractions) - Anxiety disorders or panic disorder - Insomnia or sleep disturbances - Poorly controlled hypertension - Gastroesophageal reflux disease - Certain medication interactions (e.g., some psychiatric medications, theophylline)
For these patients, decaffeinated coffee represents an acceptable alternative that may still provide hepatoprotective benefits.
Importance of Preparation and Additives: The method of preparation matters: - Filtered brewed coffee is preferred for optimal risk-benefit profile - Instant coffee is an acceptable alternative - Unfiltered coffee should be consumed cautiously in patients with cardiovascular risk factors - Minimize addition of sugar, cream, syrups, and flavored additives which may offset metabolic benefits
Holistic Context: Liver disease frequently coexists with other conditions including cardiovascular disease, type 2 diabetes, dyslipidemia, and chronic kidney disease. Coffee recommendations must be tailored to the individual patient’s complete clinical profile. For example: - A patient with cirrhosis and atrial fibrillation may need decaffeinated coffee - A patient with MASLD and severe hypertriglyceridemia should avoid unfiltered coffee - A patient with cirrhosis and esophageal varices should be cautious with hot beverages
Patient Preferences and Cultural Considerations: Coffee consumption varies widely across cultures and individuals. Some patients do not enjoy coffee or have cultural or religious reasons for avoiding it. Recommendations should be made respectfully and individualized to patient preferences. For patients who do not consume coffee, focusing on other evidence-based interventions is appropriate.
Quality of Life: For many patients, coffee consumption represents an enjoyable daily ritual that may enhance quality of life. The social and psychological aspects of coffee drinking should be acknowledged as part of its overall value.
6. Summary and Recommendations
The accumulated evidence regarding coffee consumption and liver health can be synthesized into the following key points:
Epidemiological Evidence: Regular coffee consumption, in the range of two to four cups per day, is associated with: - Approximately 40-60% lower risk of cirrhosis in observational studies across diverse populations - Approximately 40% lower risk of hepatocellular carcinoma in multiple meta-analyses - Reduced prevalence and slower progression of hepatic fibrosis in patients with fatty liver disease - Lower levels of liver enzymes and improved markers of liver health
Mechanistic Basis: The hepatoprotective effects of coffee are supported by mechanistic data demonstrating: - Potent antioxidant effects that reduce oxidative stress in hepatic tissue - Anti-inflammatory properties that attenuate chronic liver inflammation - Anti-fibrotic effects through inhibition of hepatic stellate cell activation and TGF-β signaling - Improvement in insulin sensitivity and lipid metabolism, particularly relevant for MASLD - Potential anti-carcinogenic effects that may reduce HCC risk
The presence of hundreds of bioactive compounds—including chlorogenic acids, polyphenols, diterpenes, trigonelline, and melanoidins—explains coffee’s multifaceted benefits. Importantly, both caffeinated and decaffeinated coffee demonstrate protective effects, indicating that non-caffeine components play crucial roles.
Coffee Varieties and Preparation: - From a bean variety perspective, both Arabica and Robusta coffees appear beneficial. Robusta may have higher chlorogenic acid and caffeine content, while Arabica may have higher trigonelline levels. However, human liver disease-specific trials comparing varieties are lacking, and both appear protective. - Preparation method matters significantly. Filtered brewed coffee (ground coffee with paper filtration) has the strongest evidence base and offers the best risk-benefit profile by providing hepatoprotection while removing cholesterol-raising diterpenes. - Instant coffee represents an acceptable and convenient alternative that retains substantial hepatoprotective properties. - Decaffeinated coffee may still offer benefit and should be recommended for patients who cannot tolerate caffeine due to medical conditions. - Unfiltered coffee preparations (French press, Turkish coffee) may warrant caution in patients with hyperlipidemia or cardiovascular disease due to the presence of cholesterol-raising diterpenes.
Clinical Recommendations: For patients with MASLD, chronic liver disease, or at risk for cirrhosis or HCC, clinicians may consider recommending: - Moderate coffee consumption of two to four cups per day - Preferably filtered brewed coffee for optimal benefit - Minimal additives (sugar, cream, syrups) to avoid offsetting metabolic benefits - Decaffeinated coffee for patients with caffeine contraindications - Coffee as an adjunctive measure within comprehensive lifestyle and medical management, not as a replacement for evidence-based primary therapies
Important Limitations: These recommendations are based primarily on observational data, and causality cannot be definitively established. Residual confounding may exist, and randomized controlled trials specifically testing coffee interventions in liver disease populations are needed.
Future Research Needs: Important areas for future investigation include: - Randomized controlled trials of coffee intervention in MASLD, cirrhosis, and high-risk HCC populations - Studies to define optimal dose, timing, and duration of coffee consumption - Comparative effectiveness studies of different bean varieties, roasting levels, and preparation methods - Investigation of specific bioactive compounds responsible for hepatoprotection - Studies examining coffee consumption in combination with emerging pharmacological therapies for liver disease - Research on potential mechanisms of coffee-liver interaction at molecular and cellular levels - Economic analyses of coffee as a preventive public health intervention
Concluding Statement: While interventional trials specifically in MASLD, cirrhosis prevention, or HCC risk reduction are limited, the cumulative observational evidence is compelling that coffee consumption, especially two to four cups daily of filtered brewed coffee, is likely beneficial for liver health. For the purposes of MASLD management, slowing fibrosis progression, or reducing HCC risk, coffee may be considered a low-cost, accessible, and generally safe adjunctive measure within a broader lifestyle and medical framework. Given coffee’s widespread availability, relatively low cost, and excellent safety profile in most individuals, incorporating coffee recommendations into clinical practice guidelines for liver disease management appears reasonable and potentially beneficial.
Healthcare providers should engage in individualized discussions with patients about coffee consumption, taking into account personal preferences, tolerance, comorbidities, and overall clinical context. For many patients with liver disease, the simple act of enjoying a daily cup (or cups) of coffee may represent a meaningful contribution to their liver health strategy—one that is both evidence-based and enjoyable.
7. Conclusion
The evidence presented in this chapter demonstrates that coffee consumption represents a promising, accessible, and low-cost adjunctive strategy for liver health. While interventional trials specifically testing coffee in MASLD reversal, cirrhosis prevention, or HCC risk reduction remain limited, the cumulative weight of observational evidence spanning multiple populations, study designs, and liver disease etiologies is compelling.
For patients with MASLD, those at risk for cirrhosis, or individuals in high-risk HCC populations, moderate coffee consumption—particularly two to four cups daily of filtered brewed coffee, consumed with minimal additives—appears likely to provide benefit. This recommendation should be integrated within a comprehensive approach that includes weight management, dietary modification, physical activity, treatment of underlying liver diseases, and appropriate medical management.
As our understanding of coffee’s bioactive constituents and their hepatoprotective mechanisms continues to evolve, future research should focus on conducting randomized controlled trials, defining optimal dosing and preparation parameters, identifying patients most likely to benefit, and elucidating the specific molecular pathways through which coffee exerts its protective effects. Until such trials are completed, clinicians can reasonably incorporate coffee recommendations into patient counseling, recognizing both the substantial observational evidence base and the generally favorable safety profile of moderate coffee consumption.
8. References
International Coffee Organization. (2024). World Coffee Consumption. https://ico.org/resources/trade-statistics-tables/
Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Alimentary Pharmacology & Therapeutics. 2016;43(5):562-574. doi:10.1111/apt.13523. https://pubmed.ncbi.nlm.nih.gov/26806124/. This comprehensive meta-analysis of nine studies (five cohort studies, four case-control studies) with 432,133 participants and 1,990 cirrhosis cases found that an increase of two cups of coffee per day was associated with a pooled relative risk of cirrhosis of 0.56 (95% CI 0.44-0.68), demonstrating a substantial protective effect of coffee against cirrhosis development.
Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Archives of Internal Medicine. 2006;166(11):1190-1195. doi:10.1001/archinte.166.11.1190. https://pubmed.ncbi.nlm.nih.gov/16772246/ — This study demonstrated a pooled odds ratio for developing cirrhosis of 0.61 (95% CI 0.45-0.84) for coffee drinkers versus non-drinkers, with evidence of inverse dose-response relationships between coffee consumption and liver disease markers.
Liu F, Wang X, Wu G, Chen L, Hu P, Ren H, Hu H. Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS One. 2015 Nov 10;10(11):e0142457. doi: 10.1371/journal.pone.0142457. PMID: 26556483; PMCID: PMC4640566. https://pubmed.ncbi.nlm.nih.gov/26556483/
Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. Nutrients. 2021 Aug 30;13(9):3042. doi: 10.3390/nu13093042. PMID: 34578919; PMCID: PMC8471033. https://pmc.ncbi.nlm.nih.gov/articles/PMC8471033/. This meta-analysis found that coffee consumption in NAFLD patients was significantly associated with lower odds of significant fibrosis (RR 0.65, 95% CI 0.54–0.78), suggesting coffee may slow fibrosis progression in fatty liver disease.
Bravi F, Bosetti C, Tavani A, et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clinical Gastroenterology and Hepatology. 2013;11(11):1413-1421.e1. doi:10.1016/j.cgh.2013.04.039. https://pubmed.ncbi.nlm.nih.gov/23660416/. This updated meta-analysis including 16 studies with 3,153 HCC cases found a summary RR of 0.60 (95% CI 0.50-0.71) for any coffee consumption versus none, with higher consumption associated with stronger risk reduction (RR 0.44 for high consumption), demonstrating robust inverse associations between coffee and HCC risk.
Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology. 2007;132(5):1740-1745. doi:10.1053/j.gastro.2007.03.044. https://pubmed.ncbi.nlm.nih.gov/17484871/ — This meta-analysis that included 2260 cases and 239,146 noncases found summary RRs for HCC of 0.66 (95% CI 0.55–0.78) for regular coffee consumption versus none, and for chronic liver disease mortality of 0.50 (95% CI 0.43–0.58), establishing coffee’s protective association with liver cancer and liver disease mortality.
Niezen S, Mehta M, Jiang ZG, Tapper EB. Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2032-2040.e6. doi: 10.1016/j.cgh.2021.09.042. Epub 2021 Oct 6. PMID: 34626832; PMCID: PMC8983790. https://pmc.ncbi.nlm.nih.gov/articles/PMC8983790/. This study evaluated 4,510 subjects and found link between coffee consumption and liver stiffness measurements but not with steatosis as measured by CAP among US adults.
Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology. 2017;29(2):e8-e12. doi:10.1097/MEG.0000000000000776. https://journals.lww.com/eurojgh/fulltext/2017/02000/coffee_consumption_and_risk_of_nonalcoholic_fatty.14.aspx — This systematic review and meta-analysis found that coffee drinkers had significantly lower risk of NAFLD (pooled RR 0.71, 95% CI 0.60-0.85) and lower risk of liver fibrosis among NAFLD patients (pooled RR 0.70, 95% CI 0.60-0.82).
Kositamongkol C, Kanchanasurakit S, Auttamalang C, Inchai N, Kabkaew T, Kitpark S, Chaiyakunapruk N, Duangjai A, Saokaew S, Phisalprapa P. Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis. Front Pharmacol. 2021 Dec 13;12:786596. doi: 10.3389/fphar.2021.786596. PMID: 34966282; PMCID: PMC8710778. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.786596/full. This comprehensive review indicated that numerous studies show favorable associations of coffee consumption with fatty liver disease, reduced steatosis severity, and lower prevalence of fibrosis in NAFLD patients.
Di Pietrantonio D, Pace Palitti V, Cichelli A, Tacconelli S. Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease. Foods. 2024 Jul 20;13(14):2280. doi: 10.3390/foods13142280. PMID: 39063364; PMCID: PMC11276147. https://pmc.ncbi.nlm.nih.gov/articles/PMC11276147/. This review focusing on caffeine and chlorogenic acids found that both regular and decaffeinated coffee showed preventive effects on chronic liver diseases (fibrosis, cirrhosis, HCC), indicating that non-caffeine components, particularly chlorogenic acids, contribute significantly to hepatoprotection.
Shokouh P, Jeppesen PB, Hermansen K, Nørgaard JV, Bohl M, Rezania S, Gregersen S. Efficacy of Arabica versus Robusta coffee in improving weight, insulin resistance, and liver steatosis in a rat model of type 2 diabetes. Journal of Medicinal Food. 2019;22(9):901-907. doi:10.1089/jmf.2019.0064. https://pmc.ncbi.nlm.nih.gov/articles/PMC6770458/ — This animal study demonstrated that both Arabica and Robusta coffee reduced liver steatosis and improved insulin sensitivity in a diabetic rat model, with no significant differences between the two species, supporting the hepatoprotective properties of both major coffee varieties.
Xiao Q, Sinha R, Graubard BI, Freedman ND. Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999-2010. Hepatology. 2014;60(6):2091-2098. doi:10.1002/hep.27367. https://pubmed.ncbi.nlm.nih.gov/25124935/. This large US population study found that both caffeinated and decaffeinated coffee were inversely associated with elevated liver enzyme levels (ALT, AST, GGT), supporting the role of non-caffeine components in coffee’s hepatoprotective effects and demonstrating that decaf coffee retains beneficial properties.
Godos J, Micek A, Marranzano M, et al. Coffee consumption and risk of biliary tract cancers and liver cancer: a dose-response meta-analysis of prospective cohort studies. Nutrients. 2017;9(9):950. doi:10.3390/nu9090950. https://pubmed.ncbi.nlm.nih.gov/28846640/. This dose-response meta-analysis examined the possible impact of coffee on carcinogenesis in the liver via reduction of inflammation, fibrosis (which provides substrate for HCC), and direct anti-cancer-related pathways, demonstrating inverse associations between coffee consumption and liver cancer risk.
British Liver Trust. Coffee and your liver FAQs. Updated 2023. https://britishlivertrust.org.uk/information-and-support/living-with-a-liver-condition/coffee/ — This patient information resource from the British Liver Trust states that there is good evidence that drinking coffee can reduce the risk of HCC and cirrhosis, that “it should be safe for you to drink coffee if you have a liver condition,” and that filter, instant, and decaffeinated coffee are all beneficial, though emphasizes coffee is not a substitute for medical care.
Ludwig IA, Clifford MN, Lean MEJ, Ashihara H, Crozier A. Coffee: biochemistry and potential impact on health. Food Funct. 2014;5(8):1695-1717. doi:10.1039/c4fo00042k. https://pubmed.ncbi.nlm.nih.gov/24671262/. This comprehensive review discusses Arabica and Robusta coffee varieties, their biochemical differences, and health impacts.
Jeszka-Skowron M, Sentkowska A, Pyrzyńska K, De Peña MP. Chlorogenic acids, caffeine content and antioxidant properties of green coffee extracts: influence of green coffee bean preparation. Eur Food Res Technol. 2016;242(8):1403-1409. doi:10.1007/s00217-016-2643-y — This study compares bioactive compound content between Arabica and Robusta varieties.
Kennedy OJ, Fallowfield JA, Poole R, Hayes PC, Parkes J, Roderick PJ. All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study. BMC Public Health. 2021;21:970. doi:10.1186/s12889-021-10991-7. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-10991-7. This large cohort study of 494,585 UK Biobank participants showed that decaffeinated, instant, and ground coffee all demonstrated reduced risk for incident chronic liver disease and death from chronic liver disease, with ground coffee showing the strongest protective associations.
Cai L, Ma D, Zhang Y, Liu Z, Wang P. The effect of coffee consumption on serum lipids: a meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2012;66(8):872-877. doi:10.1038/ejcn.2012.68. https://pubmed.ncbi.nlm.nih.gov/22713771/. This meta-analysis examined effects of coffee preparation methods on lipids, finding filtered coffee does not significantly affect cholesterol while unfiltered coffee raises LDL.
Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017;359:j5024. doi:10.1136/bmj.j5024. https://bmjopen.bmj.com/content/7/5/e013739. This systematic review and dose-response meta-analysis indicated that increased caffeinated coffee consumption had a stronger association with reduced HCC risk compared to decaffeinated coffee, though decaf also showed protective trends, supporting the contribution of both caffeine and non-caffeine components. the largest risk reductions at 3-4 cups/day.
Urgert R, Katan MB. The cholesterol-raising factor from coffee beans. Annu Rev Nutr. 1997;17:305-324. doi:10.1146/annurev.nutr.17.1.305. https://pubmed.ncbi.nlm.nih.gov/9240930/ — This review discusses how diterpenes (kahweol and cafestol) in unfiltered coffee raise serum cholesterol, while paper-filtered coffee contains minimal diterpenes.
Sewter R, Heaney S, Patterson A. Coffee Consumption and the Progression of NAFLD: A Systematic Review. Nutrients. 2021 Jul 12;13(7):2381. doi: 10.3390/nu13072381. PMID: 34371891; PMCID: PMC8308484. https://pubmed.ncbi.nlm.nih.gov/34371891/. This systematic review concluded that higher coffee consumption was associated with lower severity of hepatic fibrosis in individuals with NAFLD, supporting coffee’s potential role in slowing disease progression in fatty liver disease.
Other references
Wadhawan M, Anand AC. Coffee and liver disease. Journal of Clinical and Translational Hepatology. 2016;4(3):233-241. doi:10.14218/JCTH.2016.00027. https://pmc.ncbi.nlm.nih.gov/articles/PMC4862107/ — This comprehensive review summarizes the evidence for benefits of coffee in various liver diseases, including mechanisms of action, epidemiological associations, and clinical implications for patients with chronic liver disease.
Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. Caffeine in liver diseases: Pharmacology and toxicology. Front Pharmacol. 2022 Oct 17;13:1030173. doi: 10.3389/fphar.2022.1030173. PMID: 36324678; PMCID: PMC9618645. https://pmc.ncbi.nlm.nih.gov/articles/PMC9618645/. This review describes the biochemical pathways by which caffeine and chlorogenic acids (CGAs) may protect against fibrosis, cirrhosis, and HCC, including antioxidant effects, anti-inflammatory properties, and inhibition of hepatic stellate cell activation.
Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014 Sep;34(8):1250-8. doi: 10.1111/liv.12379. Epub 2013 Nov 24. PMID: 24267865; PMCID: PMC4010559. https://pubmed.ncbi.nlm.nih.gov/24267865/.
Godos J, Pluchinotta FR, Marventano S, et al. Coffee components and cardiovascular risk: beneficial and detrimental effects. International Journal of Food Sciences and Nutrition. 2014;65(8):925-936. doi:10.3109⁄09637486.2014.940287. https://pubmed.ncbi.nlm.nih.gov/25046596/. This review discusses the hundreds of bioactive compounds in coffee beyond caffeine, including chlorogenic acids, polyphenols, diterpenes (kahweol and cafestol), trigonelline, and melanoidins, and their diverse biological effects on health.